Deferiprone: Pan-selective Histone Lysine Demethylase Inhibition Activity and Structure Activity Relationship Study

Verjine Khodaverdian, Subhasish Tapadar, Ian A. MacDonald, Yuan Xu, Po Yi Ho, Allison Bridges, Pragya Rajpurohit, Bhakti A. Sanghani, Yuhong Fan, Muthusamy Thangaraju, Nathaniel A. Hathaway, Adegboyega K. Oyelere

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Deferiprone (DFP) is a hydroxypyridinone-derived iron chelator currently in clinical use for iron chelation therapy. DFP has also been known to elicit antiproliferative activities, yet the mechanism of this effect has remained elusive. We herein report that DFP chelates the Fe 2+ ion at the active sites of selected iron-dependent histone lysine demethylases (KDMs), resulting in pan inhibition of a subfamily of KDMs. Specifically, DFP inhibits the demethylase activities of six KDMs - 2A, 2B, 5C, 6A, 7A and 7B - with low micromolar IC 50 s while considerably less active or inactive against eleven KDMs - 1A, 3A, 3B, 4A-E, 5A, 5B and 6B. The KDM that is most sensitive to DFP, KDM6A, has an IC 50 that is between 7- and 70-fold lower than the iron binding equivalence concentrations at which DFP inhibits ribonucleotide reductase (RNR) activities and/or reduces the labile intracellular zinc ion pool. In breast cancer cell lines, DFP potently inhibits the demethylation of H3K4me3 and H3K27me3, two chromatin posttranslational marks that are subject to removal by several KDM subfamilies which are inhibited by DFP in cell-free assay. These data strongly suggest that DFP derives its anti-proliferative activity largely from the inhibition of a sub-set of KDMs. The docked poses adopted by DFP at the KDM active sites enabled identification of new DFP-based KDM inhibitors which are more cytotoxic to cancer cell lines. We also found that a cohort of these agents inhibited HP1-mediated gene silencing and one lead compound potently inhibited breast tumor growth in murine xenograft models. Overall, this study identified a new chemical scaffold capable of inhibiting KDM enzymes, globally changing histone modification profiles, and with specific anti-tumor activities.

Original languageEnglish (US)
Article number4802
JournalScientific Reports
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Histone Demethylases
Structure-Activity Relationship
Iron
Catalytic Domain
deferiprone
Histone Code
Ions
Breast Neoplasms
Chelation Therapy
Ribonucleotide Reductases
Cell Line
Gene Silencing
Chelating Agents
Heterografts
Chromatin
Zinc

ASJC Scopus subject areas

  • General

Cite this

Khodaverdian, V., Tapadar, S., MacDonald, I. A., Xu, Y., Ho, P. Y., Bridges, A., ... Oyelere, A. K. (2019). Deferiprone: Pan-selective Histone Lysine Demethylase Inhibition Activity and Structure Activity Relationship Study. Scientific Reports, 9(1), [4802]. https://doi.org/10.1038/s41598-019-39214-1

Deferiprone : Pan-selective Histone Lysine Demethylase Inhibition Activity and Structure Activity Relationship Study. / Khodaverdian, Verjine; Tapadar, Subhasish; MacDonald, Ian A.; Xu, Yuan; Ho, Po Yi; Bridges, Allison; Rajpurohit, Pragya; Sanghani, Bhakti A.; Fan, Yuhong; Thangaraju, Muthusamy; Hathaway, Nathaniel A.; Oyelere, Adegboyega K.

In: Scientific Reports, Vol. 9, No. 1, 4802, 01.12.2019.

Research output: Contribution to journalArticle

Khodaverdian, V, Tapadar, S, MacDonald, IA, Xu, Y, Ho, PY, Bridges, A, Rajpurohit, P, Sanghani, BA, Fan, Y, Thangaraju, M, Hathaway, NA & Oyelere, AK 2019, 'Deferiprone: Pan-selective Histone Lysine Demethylase Inhibition Activity and Structure Activity Relationship Study', Scientific Reports, vol. 9, no. 1, 4802. https://doi.org/10.1038/s41598-019-39214-1
Khodaverdian, Verjine ; Tapadar, Subhasish ; MacDonald, Ian A. ; Xu, Yuan ; Ho, Po Yi ; Bridges, Allison ; Rajpurohit, Pragya ; Sanghani, Bhakti A. ; Fan, Yuhong ; Thangaraju, Muthusamy ; Hathaway, Nathaniel A. ; Oyelere, Adegboyega K. / Deferiprone : Pan-selective Histone Lysine Demethylase Inhibition Activity and Structure Activity Relationship Study. In: Scientific Reports. 2019 ; Vol. 9, No. 1.
@article{3f36c90fbbcb4df4ac1fe5cacdb0045b,
title = "Deferiprone: Pan-selective Histone Lysine Demethylase Inhibition Activity and Structure Activity Relationship Study",
abstract = "Deferiprone (DFP) is a hydroxypyridinone-derived iron chelator currently in clinical use for iron chelation therapy. DFP has also been known to elicit antiproliferative activities, yet the mechanism of this effect has remained elusive. We herein report that DFP chelates the Fe 2+ ion at the active sites of selected iron-dependent histone lysine demethylases (KDMs), resulting in pan inhibition of a subfamily of KDMs. Specifically, DFP inhibits the demethylase activities of six KDMs - 2A, 2B, 5C, 6A, 7A and 7B - with low micromolar IC 50 s while considerably less active or inactive against eleven KDMs - 1A, 3A, 3B, 4A-E, 5A, 5B and 6B. The KDM that is most sensitive to DFP, KDM6A, has an IC 50 that is between 7- and 70-fold lower than the iron binding equivalence concentrations at which DFP inhibits ribonucleotide reductase (RNR) activities and/or reduces the labile intracellular zinc ion pool. In breast cancer cell lines, DFP potently inhibits the demethylation of H3K4me3 and H3K27me3, two chromatin posttranslational marks that are subject to removal by several KDM subfamilies which are inhibited by DFP in cell-free assay. These data strongly suggest that DFP derives its anti-proliferative activity largely from the inhibition of a sub-set of KDMs. The docked poses adopted by DFP at the KDM active sites enabled identification of new DFP-based KDM inhibitors which are more cytotoxic to cancer cell lines. We also found that a cohort of these agents inhibited HP1-mediated gene silencing and one lead compound potently inhibited breast tumor growth in murine xenograft models. Overall, this study identified a new chemical scaffold capable of inhibiting KDM enzymes, globally changing histone modification profiles, and with specific anti-tumor activities.",
author = "Verjine Khodaverdian and Subhasish Tapadar and MacDonald, {Ian A.} and Yuan Xu and Ho, {Po Yi} and Allison Bridges and Pragya Rajpurohit and Sanghani, {Bhakti A.} and Yuhong Fan and Muthusamy Thangaraju and Hathaway, {Nathaniel A.} and Oyelere, {Adegboyega K.}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-39214-1",
language = "English (US)",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Deferiprone

T2 - Pan-selective Histone Lysine Demethylase Inhibition Activity and Structure Activity Relationship Study

AU - Khodaverdian, Verjine

AU - Tapadar, Subhasish

AU - MacDonald, Ian A.

AU - Xu, Yuan

AU - Ho, Po Yi

AU - Bridges, Allison

AU - Rajpurohit, Pragya

AU - Sanghani, Bhakti A.

AU - Fan, Yuhong

AU - Thangaraju, Muthusamy

AU - Hathaway, Nathaniel A.

AU - Oyelere, Adegboyega K.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Deferiprone (DFP) is a hydroxypyridinone-derived iron chelator currently in clinical use for iron chelation therapy. DFP has also been known to elicit antiproliferative activities, yet the mechanism of this effect has remained elusive. We herein report that DFP chelates the Fe 2+ ion at the active sites of selected iron-dependent histone lysine demethylases (KDMs), resulting in pan inhibition of a subfamily of KDMs. Specifically, DFP inhibits the demethylase activities of six KDMs - 2A, 2B, 5C, 6A, 7A and 7B - with low micromolar IC 50 s while considerably less active or inactive against eleven KDMs - 1A, 3A, 3B, 4A-E, 5A, 5B and 6B. The KDM that is most sensitive to DFP, KDM6A, has an IC 50 that is between 7- and 70-fold lower than the iron binding equivalence concentrations at which DFP inhibits ribonucleotide reductase (RNR) activities and/or reduces the labile intracellular zinc ion pool. In breast cancer cell lines, DFP potently inhibits the demethylation of H3K4me3 and H3K27me3, two chromatin posttranslational marks that are subject to removal by several KDM subfamilies which are inhibited by DFP in cell-free assay. These data strongly suggest that DFP derives its anti-proliferative activity largely from the inhibition of a sub-set of KDMs. The docked poses adopted by DFP at the KDM active sites enabled identification of new DFP-based KDM inhibitors which are more cytotoxic to cancer cell lines. We also found that a cohort of these agents inhibited HP1-mediated gene silencing and one lead compound potently inhibited breast tumor growth in murine xenograft models. Overall, this study identified a new chemical scaffold capable of inhibiting KDM enzymes, globally changing histone modification profiles, and with specific anti-tumor activities.

AB - Deferiprone (DFP) is a hydroxypyridinone-derived iron chelator currently in clinical use for iron chelation therapy. DFP has also been known to elicit antiproliferative activities, yet the mechanism of this effect has remained elusive. We herein report that DFP chelates the Fe 2+ ion at the active sites of selected iron-dependent histone lysine demethylases (KDMs), resulting in pan inhibition of a subfamily of KDMs. Specifically, DFP inhibits the demethylase activities of six KDMs - 2A, 2B, 5C, 6A, 7A and 7B - with low micromolar IC 50 s while considerably less active or inactive against eleven KDMs - 1A, 3A, 3B, 4A-E, 5A, 5B and 6B. The KDM that is most sensitive to DFP, KDM6A, has an IC 50 that is between 7- and 70-fold lower than the iron binding equivalence concentrations at which DFP inhibits ribonucleotide reductase (RNR) activities and/or reduces the labile intracellular zinc ion pool. In breast cancer cell lines, DFP potently inhibits the demethylation of H3K4me3 and H3K27me3, two chromatin posttranslational marks that are subject to removal by several KDM subfamilies which are inhibited by DFP in cell-free assay. These data strongly suggest that DFP derives its anti-proliferative activity largely from the inhibition of a sub-set of KDMs. The docked poses adopted by DFP at the KDM active sites enabled identification of new DFP-based KDM inhibitors which are more cytotoxic to cancer cell lines. We also found that a cohort of these agents inhibited HP1-mediated gene silencing and one lead compound potently inhibited breast tumor growth in murine xenograft models. Overall, this study identified a new chemical scaffold capable of inhibiting KDM enzymes, globally changing histone modification profiles, and with specific anti-tumor activities.

UR - http://www.scopus.com/inward/record.url?scp=85063039916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063039916&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-39214-1

DO - 10.1038/s41598-019-39214-1

M3 - Article

C2 - 30886160

AN - SCOPUS:85063039916

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 4802

ER -